A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis
Non-adherence to anti-tubercular therapy Mycobacterium tuberculosis infection can lead to treatment failure and even the development of drug resistance. In this work, the authors develop a long-acting delivery system of the anti-tuberculosis drug rifabutin and assess translational potential in vivo.
Bibliographic Details
| Main Authors: |
Manse Kim,
Claire E. Johnson,
Alan A. Schmalstig,
Ayano Annis,
Sarah E. Wessel,
Brian Van Horn,
Amanda Schauer,
Agata A. Exner,
Jason E. Stout,
Angela Wahl,
Miriam Braunstein,
J. Victor Garcia,
Martina Kovarova |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Portfolio
2022-08-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-022-32043-3
|
|---|